share_log

Mangoceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Cohen Jacob D.

SEC ·  Jun 6 05:17
Summary by Futu AI
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Jacob D. Cohen, the Chief Executive Officer of Mangoceuticals, Inc. (MGRX), completed a significant stock transaction on June 3, 2024. Cohen was granted 800,000 shares of common stock at no cost, as per the transaction details released. Following this grant, Cohen directly holds a total of 800,000 shares in the company. The transaction, which was classified as a grant, indicates a strengthening of the CEO's stake in Mangoceuticals, potentially signaling confidence in the company's future prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.